A new clinical trial from drugmaker Eli Lilly shows that Zepbound and Mounjaro reduced obstructive sleep apnea symptoms.
The U.S. Food and Drug Administration (FDA) approved Zepbound for the treatment of obesity in November 2023. Some prescribe ...
Zepbound, a popular weight loss drug, also seems to help people with obstructive sleep apnea, drugmaker Eli Lilly said ...
In a new study, people with obesity who received weight-loss drug Zepbound saw a greater average reduction in sleep apnea ...
The company reported results of clinical trials involving Zepbound, an obesity drug in the same class as Novo Nordisk’s ...
Weight loss drugs like Ozempic and Mounjaro have gained great traction in recent months, and now drugmakers have found ...
The weight-loss drug Zepbound was linked to a reduction in obstructive sleep apnea (OSA), according to new research.
Eli Lilly announced today that the drug behind Zepbound was found to help alleviate sleep apnea in patients with obesity in ...
Eli Lilly’s weight loss drug Zepbound was found to reduce obstructive sleep apnea in adults with obesity, the drugmaker said ...
The unpublished results are the latest in a string of signs weight loss drugs may treat a variety of other conditions, too.
Eli Lilly said that after conducting two late-stage trials its weight-loss drug Zepbound has been proven to reduce sleep ...